Short Interest in SAB Biotherapeutics, Inc. (NASDAQ:SABS) Declines By 19.4%

SAB Biotherapeutics, Inc. (NASDAQ:SABS) was the target of a large decrease in short interest in March. As of March 31st, there was short interest totalling 92,700 shares, a decrease of 19.4% from the March 15th total of 115,000 shares. Based on an average daily trading volume, of 107,200 shares, the short-interest ratio is currently 0.9 days. Approximately 1.2% of the company’s stock are sold short.

SAB Biotherapeutics Stock Performance

NASDAQ SABS traded down $0.01 during trading on Monday, reaching $1.43. The company’s stock had a trading volume of 53,700 shares, compared to its average volume of 61,593. The business’s fifty day moving average price is $1.54 and its 200-day moving average price is $2.66. SAB Biotherapeutics has a twelve month low of $1.00 and a twelve month high of $5.01. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.69 and a current ratio of 3.69. The firm has a market cap of $13.25 million, a price-to-earnings ratio of -0.39 and a beta of 0.52.

SAB Biotherapeutics (NASDAQ:SABS) last released its quarterly earnings results on Friday, March 28th. The company reported ($1.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.07). The company had revenue of $0.05 million for the quarter, compared to analysts’ expectations of $0.12 million. SAB Biotherapeutics had a negative return on equity of 94.37% and a negative net margin of 1,450.14%. As a group, analysts anticipate that SAB Biotherapeutics will post -3.69 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of SABS. Northern Trust Corp acquired a new position in SAB Biotherapeutics in the 4th quarter valued at $43,000. Geode Capital Management LLC increased its stake in shares of SAB Biotherapeutics by 18.8% during the fourth quarter. Geode Capital Management LLC now owns 80,234 shares of the company’s stock worth $307,000 after acquiring an additional 12,692 shares during the period. Silver Oak Securities Incorporated purchased a new position in SAB Biotherapeutics during the first quarter worth about $30,000. Diadema Partners LP purchased a new stake in SAB Biotherapeutics in the 4th quarter valued at approximately $114,000. Finally, HB Wealth Management LLC increased its position in SAB Biotherapeutics by 118.6% during the 4th quarter. HB Wealth Management LLC now owns 237,400 shares of the company’s stock worth $982,000 after purchasing an additional 128,800 shares during the period. Institutional investors and hedge funds own 7.82% of the company’s stock.

Analysts Set New Price Targets

SABS has been the subject of a number of research reports. HC Wainwright reissued a “buy” rating and issued a $6.00 price target on shares of SAB Biotherapeutics in a research report on Tuesday, April 1st. Chardan Capital reduced their target price on SAB Biotherapeutics from $25.00 to $20.00 and set a “buy” rating for the company in a report on Tuesday, April 1st. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, SAB Biotherapeutics currently has an average rating of “Buy” and a consensus target price of $11.40.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.